Auralis Bio expands spray-drying capacity for clinical-scale amorphous dispersions
New process and analytical capability shortens the path from feasibility screen to first GMP clinical supply for solubility-limited candidates.
Read more →Enabling formulation & drug delivery
Turning poorly absorbed molecules into viable medicines.
Auralis Bio is a specialist development partner for small-molecule programmes held back by bioavailability. We engineer enabling formulation and drug delivery strategies that overcome poor solubility and first-pass metabolism — enhancing systemic exposure and clearing the path to the clinic.
The challenge
When a promising molecule can't get into the blood
An estimated 4 in 10 development candidates — and the majority of modern discovery libraries — suffer from poor aqueous solubility. The result is low oral exposure, high variability, and a pharmacokinetic profile that stalls a programme before it reaches patients. We exist to fix that one molecule at a time.
Bioavailability toolbox
The right enabling technology for each molecule
Technology
Mechanism
Best suited to
Spray-dried dispersionsAmorphous solid dispersion
MechanismSolubility enhancement
Best suited toLow-solubility, high-melting compounds
End-to-end
Lipid-based deliverySEDDS / SMEDDS
MechanismSolubilisation & first-pass bypass
Best suited toLipophilic, first-pass-limited compounds
End-to-end
Why Auralis
A focused partner, not a production line.
Mechanism-led
We diagnose why exposure is low — solubility, dissolution rate, permeability, or first-pass metabolism — then select the technology that addresses the actual rate-limiting step.
Phase-appropriate
From a few milligrams of API for a screen to GMP clinical supply — we scale the science to your stage and conserve precious material at every step.
Translation-ready
Every formulation is designed with developability, stability, and a credible CMC and regulatory story in mind — so early wins survive the journey to the clinic.
Latest news
What's new at Auralis Bio
Case study: 9-fold increase in oral exposure for a first-pass-limited candidate
A lipid-based delivery system raised relative bioavailability in preclinical models, enabling the partner to progress toward IND.
Read more →Auralis Bio joins consortium advancing predictive biopharmaceutics
The collaboration applies PBPK modelling to link in vitro formulation performance to in vivo exposure earlier in development.
Read more →Have a molecule with a bioavailability problem?
Send us the PK picture and the hurdle you're facing. We'll tell you candidly whether an enabling formulation can move the needle.